BIOCYTOGEN-B (02315) surged over 5% in morning trading. As of press time, the stock was up 4.83% to HK$24.76, with turnover of HK$7.44 million.

On the news front, BIOCYTOGEN-B recently released its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 621 million, representing a 51.3% year-on-year increase. Profit attributable to shareholders reached RMB 47.999 million, turning from loss to profit compared to the same period last year. Earnings per share stood at RMB 0.12.

In the first half of 2025, the company's preclinical products and services business, centered on innovative animal model sales, achieved operating revenue of RMB 458 million, up 56.9% from the same period last year, while maintaining a high gross margin of approximately 70%. As another core driver of the company's performance growth, the antibody discovery business generated operating revenue of RMB 163 million in the first half of 2025, up 37.8% year-on-year, with a gross margin of approximately 90%.

Built on globally leading gene editing technology, BIOCYTOGEN has successfully established a dual-engine growth model centered on innovative animal models and antibody molecule licensing and development, creating a distinctive platform-based innovative biotech path that differs from traditional CROs and pharmaceutical companies.

Notably, leveraging its RenMice series fully human antibody mouse platform, the "Thousand Mice, Ten Thousand Antibodies" program, and a global patent network, the company has gradually built dual moats in technology and patents, forming competitive barriers that are difficult to replicate. As BIOCYTOGEN accelerates in establishing its industry position as a "global new drug origin," its long-term growth value and investment attractiveness continue to enhance.